Polycystic ovary syndrome is a highly heterogeneous endocrine disorder characterized by concurrent reproductive dysfunction and metabolic abnormalities. The core pathogenesis of the syndrome entails multiple interrelated pathological processes, notably dysfunction of the hypothalamic-pituitary-ovarian axis, insulin resistance, hyperandrogenemia, and chronic low-grade inflammation. While an expanding body of scientific evidence indicates that mitochondrial dysfunction is closely associated with polycystic ovary syndrome, researchers emphasize that the definitive causal relationship between the two has not yet been fully elucidated.
Writing in the Journal of Ovarian Research, a research team critically evaluated published evidence across in vitro cell models, animal experiments, and human clinical trials. The primary focus of the review is to investigate where mitochondrial dysfunction fits within the broader mitochondrial-metabolic-inflammatory axis. Specifically, the authors assessed whether mitochondrial impairment operates as an initiating factor, a secondary consequence, or an amplifying factor in driving the clinical abnormalities observed in individuals with the disorder.
The review details specific mitochondrial alterations associated with distinct phenotypes of polycystic ovary syndrome, alongside potential candidate biomarkers for monitoring cellular impairment. Furthermore, the authors synthesize emerging research insights derived from multi-omics analyses and single-cell technologies.
A central finding highlighted in the analysis is that mitochondrial dysfunction contributes to establishing a complex bidirectional regulatory network. Within this biological circuit, mitochondrial deficits do not act in isolation; instead, they interact reciprocally with chronic metabolic stress, persistent low-grade inflammation, and ovarian dysfunction, potentially reinforcing each component of the pathological cycle across different disorder manifestations.
Finally, the authors examine the underlying molecular mechanisms while critically highlighting the limitations of current clinical evidence.
Subject of Research: Mitochondrial dysfunction mechanisms and clinical translation in polycystic ovary syndrome
Article Title: Mitochondrial dysfunction in polycystic ovary syndrome: mechanistic insights and therapeutic opportunities
Article References: San, S., Chu, F., Meng, K., Shen, L., & Xing, H. (2026). Mitochondrial dysfunction in polycystic ovary syndrome: mechanistic insights and therapeutic opportunities. Journal of Ovarian Research. https://doi.org/10.1186/s13048-026-02356-8
Image Credits: AI Generated
DOI: 10.1186/s13048-026-02356-8
Keywords: polycystic ovary syndrome, mitochondrial dysfunction, reproductive dysfunction, metabolic abnormalities, hypothalamic-pituitary-ovarian axis, insulin resistance, hyperandrogenemia, chronic low-grade inflammation, mitochondrial-metabolic-inflammatory axis, in vitro studies, animal experiments, candidate biomarkers, multi-omics, single-cell technologies, bidirectional regulatory network, mitochondrial interventions, ovarian dysfunction
News Source: Ophelia Keating. (November 18, 2026). Review Assesses Mitochondrial Dysfunction in Polycystic Ovary Syndrome Pathogenesis. Scienmag.



